|Home Page : www.otcjournal.com
Email Questions or Comments To: firstname.lastname@example.org
OTC Journal Members:
In the last week I've made the call on two different stocks that were streaking, and corrected to provide a better entry point for those who either missed the first run, or traded out for a profit.
One gigantic win, and one fizzled. In Major League Baseball with a bat in your hand, that will get you millions. In small stocks, it's still pretty darn good- after all, stocks go only go to zero- there's no ceiling as to how high they can go.
My win- calling the bounce in Luxeyard (LUXR)- which looks like it could make a new all time high today or tomorrow. As I disclosed in a previous edition, I sold some of the shares I own the last time the stock was close to the $1.20 level- I still own most of it- not this time- I believe the stock is destined to surpass $1.50 and might even find $2. Putting all the ups and downs aside, I picked it at $.80 on April 12th- $1.15 today for a 44% gain.
Yesterday call for a bounce on American Liberty (OREO) was premature- it appears I missed it by a day. If you pick it up on the open, you're in at $1.40- now $1.30, but below my SSL of $1.30, so you might be out. The stock could still set up for a rally, and the volume is coming in nicely.
Perhaps unnoticed in yesterday's trading was the big bounce in Nuvilex (NVLX)- which I called at $.06 back on March 18th. I'm sticking with this one for six months. I love the technology they're working on. The stock has been quiet of late, but hit $.077 yesterday on huge volume- interest in surfacing. Net gain on that one 28% from day 1.
I'm calling it - right here, right now. It's sometimes tough to call the streaking stocks- up and down. Sometimes you just don't hit the number perfectly. So, if you want to make money, and want to get in ahead of the crowd, perhaps it makes sense to look at one that is quiet, down, under followed, and no one wants. Then, when the market goes nuts for the stock, you can be a seller and notch some significant gains when everyone else is piling in.
I'd ask you to look back at my presentation on Plandai Biotech (PLPL)- back on March 26th. If you want to read the original presentation, simply go back and click on the date. At the time, the stock was $.25, and it's quietly hovering just above my SSL of $.18- $.20 bid- but offered at $.245- we started at $.25, so no damage done on this one- still plenty of upside.
If you read the original presentation, this company is a combination Ag/Technology story that has developed a revolutionary new method for processing Green Tea Extract- a substance that is in high demand. This company is making the stuff 10 times more powerful than anyone else on Earth.
The company will be commercializing its product in South Africa with a debt financing of $13 million from the South African government, but the loan has not closed yet. When it does, I suspect the stock will go bonkers. It's impossible to predict how high it will go, but the stock hit $.75 when the agreement was announced.
Today- in quiet trading, it's about $.25.
I can't guarantee it will head back to $.75- but I suspect the company is getting very close to closing this transaction, and once announced the stock will have a new life.
So, it you're tired of chasing these stocks up and down the charts and trying to get on the right side of a trade, you want to own this one ahead of the closing, which I believe is imminent. If just makes too much sense from an economic development stand point.
Accumulate PLPL today while no one is paying attention. Look what happened with NVLX yesterday. Others have surged out of nowhere. Have a 2 to 4 week window in time, but don't be surprised if the fireworks happen in short order. It simply makes too much sense- the South African government needs employers in these ag regions, and this company is perfectly positioned to put a mere $13 million to work- that's chump change on a government scale, but huge for PLPL shareholders.
The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.
All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.
The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.